

03 - 18 - 02 SN: 10/009,009  
JG07 Rec'd PCT/PTO T 3 MAR 2002 # 8

CASE 4-30972A  
9/23/02  
8W



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV 041586262US Express Mail Label Number	March 14, 2002 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 09 2002

TECH CENTER 1600/290

IN RE PCT NATIONAL STAGE APPLICATION OF  
BRAIN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP00/05059

FILED: 2 JUNE 2000

U.S. APPLICATION NO: 10/009,009

35 USC §371 DATE: 3 DECEMBER 2001

FOR: BRADYKININ RECEPTOR ANTAGONISTS

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed reference WO 9725315 A was cited in the international stage search report, a copy of which is enclosed herewith. Since the listed reference is of record in the instant PCT application PCT/EP00/05059, a copy is not enclosed. Applicants are enclosing U.S. Patent 6,100,278, which they believe to be substantially equivalent to WO 97/25315A.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6932

Date: *March 14, 2002*

Respectfully submitted,

  
\_\_\_\_\_  
Carol A. Loeschorn  
Attorney for Applicants  
Reg. No. 35,590